April 9th 2024
The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.
Intraocular inflammation: A major risk factor resulting from use of anti-complement agents for GA
March 15th 2024The good news for patients is that GA is transitioning from an untreatable disease to a potentially treatable one with development of new therapies to reduce the growth rate, and use of anti-complement therapies have caused the growth rate of GA lesions to decrease.
PulseSight Therapeutics launches to advance non-viral gene therapies for severe retinal diseases
March 1st 2024According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.
AAO 2023: AVD-104 and the results of the phase II/III part 1 SIGLEC trial
November 26th 2023Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.